MCID: ANG020
MIFTS: 53

Angiosarcoma malady

Categories: Cardiovascular diseases, Fetal diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Angiosarcoma

Aliases & Descriptions for Angiosarcoma:

Name: Angiosarcoma 12 56 52 14
Hemangiosarcoma 12 42 69

Characteristics:

Orphanet epidemiological data:

56
angiosarcoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0001816
MeSH 42 D006394
NCIt 47 C3088 C9275
Orphanet 56 ORPHA263413
ICD10 via Orphanet 34 C49.9

Summaries for Angiosarcoma

Disease Ontology : 12 A malignant Vascular tumor that results_in rapidly proliferating, extensively infiltrating anaplastic cells derives from blood vessels and derived_from the lining of irregular blood-filled spaces.

MalaCards based summary : Angiosarcoma, also known as hemangiosarcoma, is related to spleen angiosarcoma and mediastinum angiosarcoma. An important gene associated with Angiosarcoma is FLT4 (Fms Related Tyrosine Kinase 4), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Ethiodized oil and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include breast, liver and bone, and related phenotypes are Increased senescence-associated beta-galactosidase protein expression after pRB stimulation and cardiovascular system

Wikipedia : 71 Angiosarcoma is a cancer of the cells that line the walls of blood vessels or lymphatic vessels. The... more...

Related Diseases for Angiosarcoma

Diseases related to Angiosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 285)
id Related Disease Score Top Affiliating Genes
1 spleen angiosarcoma 33.2 MUC1 VIM
2 mediastinum angiosarcoma 32.9 MUC1 TP53 VIM
3 adenosarcoma 29.3 KIT MUC1 TP53 VIM
4 gastrointestinal stromal tumor 29.2 KIT TP53 VEGFA VIM
5 mitral valve stenosis 28.6 FLI1 FLT1 FLT4 KDR KIT VEGFA
6 hemolytic anemia 28.5 FLT1 FLT4 KDR PECAM1 PROX1 TEK
7 liver angiosarcoma 12.2
8 breast angiosarcoma 12.2
9 thyroid angiosarcoma 12.1
10 pediatric angiosarcoma 12.1
11 skin angiosarcoma 12.1
12 angiosarcoma of the scalp 12.1
13 prostate angiosarcoma 12.1
14 aorta angiosarcoma 12.0
15 ovarian angiosarcoma 11.9
16 conventional angiosarcoma 11.9
17 radiation induced angiosarcoma of the breast 11.9
18 central nervous system angiosarcoma 11.9
19 superior vena cava angiosarcoma 11.8
20 lymphangiosarcoma 11.6
21 epithelioid hemangioendothelioma 11.2
22 hemangioendothelioma 11.1
23 intravascular papillary endothelial hyperplasia 11.1
24 pseudoangiomatous stromal hyperplasia 10.7
25 bone angioendothelial sarcoma 10.7
26 isolated anterior cervical hypertrichosis 10.3 VEGFA VIM
27 intracranial cysts 10.2 FLT4 VEGFA
28 mood disorder 10.2 KIT MYC
29 alcohol-induced mental disorder 10.2 KDR KIT VIM
30 multifocal osteogenic sarcoma 10.2 KDR KIT MYC
31 lysteria monocytoigeneses meningitis 10.2 FLT4 PROX1
32 benign idiopathic neonatal seizures 10.2 KDR PECAM1 VEGFA
33 kidney osteogenic sarcoma 10.2 FLT1 KDR VEGFA
34 hypomelanosis of ito 10.2 FLT4 PROX1
35 pilomyxoid astrocytoma 10.2 FLT4 PROX1
36 intracranial sinus thrombosis 10.2 KIT VIM
37 ovarian disease 10.2 FLT1 KDR VEGFA
38 pustulosis palmaris et plantaris 10.2 KDR KIT PECAM1
39 intracranial hypotension 10.2 KDR PROX1 VEGFA
40 hepatitis 10.2
41 gapo syndrome 10.2 FLT4 KDR
42 fallopian tube carcinosarcoma 10.2 MYC TP53 VEGFA
43 vernal conjunctivitis 10.2 FLT1 KDR VEGFA
44 invasive mole 10.2 KIT MUC1
45 oculodentodigital dysplasia 10.2 FLT4 PROX1
46 postpartum depression 10.2 KIT MYC TP53
47 degenerative disc disease 10.2 TEK VEGFA VWF
48 ossifying fibromyxoid tumor 10.2 TP53 VIM VWF
49 cleft palate cardiac defect ectrodactyly 10.1 KDR TP53 VEGFA
50 eosinophilic pneumonia 10.1 FLT4 KDR

Graphical network of the top 20 diseases related to Angiosarcoma:



Diseases related to Angiosarcoma

Symptoms & Phenotypes for Angiosarcoma

GenomeRNAi Phenotypes related to Angiosarcoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased senescence-associated beta-galactosidase protein expression after pRB stimulation GR00230-A-2 8.8 FLT1 KIT TEK

MGI Mouse Phenotypes related to Angiosarcoma:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.41 FLI1 FLT1 FLT4 KDR KIT KRT8
2 hematopoietic system MP:0005397 10.32 FLI1 FLT1 KDR KIT KRT8 MYC
3 homeostasis/metabolism MP:0005376 10.31 KIT KRT8 MYC PECAM1 PROX1 TEK
4 cellular MP:0005384 10.3 FLI1 FLT1 KDR KIT MYC PECAM1
5 immune system MP:0005387 10.29 FLI1 FLT1 FLT4 KDR KIT KRT8
6 embryo MP:0005380 10.28 FLI1 FLT1 FLT4 KDR KIT KRT8
7 growth/size/body region MP:0005378 10.26 FLI1 FLT1 FLT4 KDR KIT KRT8
8 mortality/aging MP:0010768 10.25 FLI1 FLT1 FLT4 KDR KIT KRT8
9 digestive/alimentary MP:0005381 10.2 FLT4 KIT KRT8 MYC PECAM1 PROX1
10 liver/biliary system MP:0005370 10.16 KDR KIT KRT8 MYC PECAM1 PROX1
11 muscle MP:0005369 10.14 FLI1 FLT1 FLT4 KDR KIT MYC
12 nervous system MP:0003631 10.11 FLI1 FLT1 KDR KIT MYC PROX1
13 normal MP:0002873 9.91 FLT1 FLT4 KDR KIT MYC PROX1
14 no phenotypic analysis MP:0003012 9.87 FLT4 KDR KIT MYC TP53 VEGFA
15 reproductive system MP:0005389 9.76 FLT1 FLT4 KIT KRT8 MYC TP53
16 respiratory system MP:0005388 9.5 VEGFA VIM TP53 KDR KIT PECAM1
17 vision/eye MP:0005391 9.23 PROX1 TEK TP53 VEGFA VIM FLT1

Drugs & Therapeutics for Angiosarcoma

Drugs for Angiosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethiodized oil Approved Phase 4 8008-53-5
2
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
4
Mechlorethamine Approved Phase 3,Phase 1 51-75-2 4033
5
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
6
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
7
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 498142 38904
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
9
Lenograstim Approved Phase 3,Phase 2 135968-09-1
10
Dactinomycin Approved Phase 3,Phase 2 50-76-0 2019 457193
11
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
12
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
13
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
14
Cyproheptadine Approved Phase 3 129-03-3 2913
15
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
16 Alkylating Agents Phase 3,Phase 2,Phase 1
17 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
18 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
19 Isophosphamide mustard Phase 3,Phase 2,Phase 1
20 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
21 Antimitotic Agents Phase 3,Phase 2
22 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
23 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
24 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
25 Etoposide phosphate Phase 3,Phase 2
26 Immunoglobulins Phase 3,Phase 1,Phase 2
27 Anti-Infective Agents Phase 3,Phase 2
28 Antibodies, Monoclonal Phase 3,Phase 1,Phase 2
29 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
30 Antibodies Phase 3,Phase 1,Phase 2
31 Antirheumatic Agents Phase 3,Phase 2,Phase 1
32 Neurotransmitter Agents Phase 3,Phase 1,Phase 2
33
Histamine Phosphate Phase 3 51-74-1 65513
34
Serotonin Phase 3 50-67-9 5202
35 Serotonin Agents Phase 3
36 Serotonin Antagonists Phase 3
37 Gastrointestinal Agents Phase 3
38 Histamine Antagonists Phase 3
39 Histamine H1 Antagonists Phase 3
40 Dermatologic Agents Phase 3
41 Anti-Allergic Agents Phase 3
42 Antipruritics Phase 3
43
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
44
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
45
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
46
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
47
Bevacizumab Approved, Investigational Phase 2 216974-75-3
48
Gemcitabine Approved Phase 2 95058-81-4 60750
49
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
50
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062

Interventional clinical trials:

(show top 50) (show all 62)
id Name Status NCT ID Phase
1 Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. Not yet recruiting NCT02625389 Phase 4
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Unknown status NCT00346164 Phase 3
3 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3
4 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3
5 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3
6 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3
7 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
8 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
9 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
10 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3
11 A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA Recruiting NCT02979899 Phase 3
12 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
13 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
14 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3
15 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
16 Paclitaxel + Bevacizumab (Avastin®) for the Treatment of Metastatic or Unresectable Angiosarcoma Unknown status NCT01055028 Phase 2
17 Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery Unknown status NCT00874874 Phase 2
18 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2
19 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2
20 Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery Completed NCT01623869 Phase 2
21 Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery Completed NCT00217607 Phase 2
22 Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Completed NCT00887809 Phase 2
23 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2
24 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2
25 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2
26 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2
27 S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas Completed NCT00217620 Phase 2
28 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2
29 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2
30 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2
31 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2
32 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2
33 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2
34 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2
35 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2
36 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2
37 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors Completed NCT00025441 Phase 2
38 Evaluation of Votrient in Angiosarcoma Recruiting NCT02212015 Phase 2
39 Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma Recruiting NCT01462630 Phase 2
40 Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma Recruiting NCT02048722 Phase 2
41 A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma Recruiting NCT01975519 Phase 1, Phase 2
42 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2
43 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2
44 Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Recruiting NCT02815995 Phase 2
45 Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas Active, not recruiting NCT01303497 Phase 2
46 Bevacizumab in Treating Patients With Angiosarcoma Active, not recruiting NCT00288015 Phase 2
47 A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas Active, not recruiting NCT01140737 Phase 2
48 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Active, not recruiting NCT01614795 Phase 2
49 Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Tria Not yet recruiting NCT02732678 Phase 1, Phase 2
50 Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma Completed NCT00720174 Phase 1

Search NIH Clinical Center for Angiosarcoma

Cochrane evidence based reviews: hemangiosarcoma

Genetic Tests for Angiosarcoma

Anatomical Context for Angiosarcoma

MalaCards organs/tissues related to Angiosarcoma:

39
Breast, Liver, Bone, Endothelial, Thyroid, Lung, Skin

Publications for Angiosarcoma

Articles related to Angiosarcoma:

(show top 50) (show all 859)
id Title Authors Year
1
Case report: whole exome sequencing of primary cardiac angiosarcoma highlights potential for targeted therapies. ( 28056866 )
2017
2
Inhibition of HSP90 exerts anti-tumor effect on angiosarcoma: Involvement of VEGF signaling pathway. ( 28078663 )
2017
3
Prognostic impact of LAT1 and CD98 expression in cutaneous angiosarcoma. ( 28052681 )
2017
4
Angiosarcoma of the Adrenal Gland Treated Using a Multimodal Approach. ( 27920990 )
2017
5
Aspergillus Terreus Brain Abscess Complicated by Tension Pneumocephalus in a Patient with Angiosarcoma. ( 28070116 )
2017
6
Angiosarcoma arising in the non-operated, sclerosing breast after primary irradiation, surviving 6 years post-resection: A case report and review of the Japanese literature. ( 27179333 )
2016
7
Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma. ( 27613162 )
2016
8
Spontaneous Ureteral Urine Extravasation From Invasion of a High-grade Angiosarcoma. ( 27617212 )
2016
9
Uterine carcinosarcoma including angiosarcoma: A short case report. ( 27592347 )
2016
10
A Korean single-center, real-world, retrospective study of first-line weekly paclitaxel in patients with metastatic angiosarcoma. ( 27175275 )
2016
11
Use of Intraoperative Indocyanine Green Videoangiography to Guide Cutaneous Angiosarcoma Excision. ( 27536487 )
2016
12
Angiosarcoma in the chest: radiologic-pathologic correlation: Case report. ( 27902593 )
2016
13
Angiosarcoma of the Right Atrium with Extension to SVC and IVC Presenting with Complete Heart Block and Significant Pericardial Effusion. ( 27110407 )
2016
14
Angiosarcoma Arising in Ovarian Mucinous Tumor: A Challenge in Intraoperative Frozen Section Diagnosis. ( 27872782 )
2016
15
Splenic Angiosarcoma: A Diagnostic Splenectomy Finding. ( 27920710 )
2016
16
MYC immunohistochemistry in angiosarcoma and atypical vascular lesions: practical considerations based on a single institutional experience. ( 27780597 )
2016
17
Liver Angiosarcoma: Rare tumour associated with a poor prognosis, literature review and case report. ( 27718433 )
2016
18
Sarcomas of the Breast with a Spotlight on Angiosarcoma and Cystosarcoma Phyllodes. ( 27591494 )
2016
19
Clinical and dermoscopic features of atypical abdominal brachytherapy-induced angiosarcoma. ( 27605906 )
2016
20
Radiation-Induced Breast Angiosarcoma: Case Report and Clinical Approach. ( 26848144 )
2016
21
Primary breast angiosarcoma in a young woman. ( 27232295 )
2016
22
Pancreatic metastasis of angiosarcoma (Stewart-Treves syndrome) diagnosed using endoscopic ultrasound-guided fine needle aspiration: A case report. ( 27537557 )
2016
23
miR-497-5p inhibits cell proliferation and invasion by targeting KCa3.1 in angiosarcoma. ( 27531900 )
2016
24
Small bowel perforation due to indistinguishable metastasis of angiosarcoma: case report and brief literature review. ( 27156097 )
2016
25
Cutaneous Angiosarcoma Simulating as Pyoderma in a Middle-aged Indian female: A Rare Case Report. ( 27904196 )
2016
26
Radiation-Associated Angiosarcoma of the Breast: Clinical and Pathologic Features. ( 27128306 )
2016
27
Pleural Myiasis Associated With Pleural Angiosarcoma. ( 27287590 )
2016
28
Angiosarcoma of the Heart Presenting as SubacuteA Pericarditis. ( 28043397 )
2016
29
Statistics and outlook of primary hepatic angiosarcoma based on clinical stage. ( 27123094 )
2016
30
Imaging features of soft tissue epithelioid angiosarcoma in the lower extremity: A case report. ( 27123135 )
2016
31
Breast Angiosarcoma with Exophytic Growth. ( 27845552 )
2016
32
A rare case of primary epithelioid angiosarcoma of the ureter. ( 27502347 )
2016
33
P2.15: Treatment Outcome of Metastatic Breast Angiosarcoma to the Lung, inA aA Reference Hospital in Latin America: AA Case Report: Track: Pathology. ( 27676551 )
2016
34
Contrast-enhanced ultrasound in diagnosis of primary hepatic angiosarcoma. ( 27909829 )
2016
35
Detection of rapidly progressing hepatic angiosarcoma on autopsy that would have definitely been diagnosable on percutaneous liver biopsy. ( 27151481 )
2016
36
Recurrent cutaneous angiosarcoma of the ear masquerading as atypical fibroxanthoma. ( 27981214 )
2016
37
Primary Thyroid Angiosarcoma with Tracheal Invasion. ( 27150873 )
2016
38
Awareness of primary spontaneous hemorrhagic angiosarcoma of the breast associated with Kasabach-Merritt syndrome in a pregnant woman by enhanced magnetic resonance imaging: A CARE-compliant case report. ( 27858895 )
2016
39
Visceral metastatic angiosarcoma treated effectively with oral cyclophosphamide combined with propranolol. ( 28004027 )
2016
40
Primary pulmonary artery angiosarcoma mimicking pulmonary embolism in a 66-year-old man with dyspnea. ( 27527482 )
2016
41
Primary Angiosarcoma of the Spleen: Rare Diagnosis with Atypical Clinical Course. ( 27867672 )
2016
42
Advances in Image-Guided Radiation Therapy for Primary Cardiac Angiosarcoma: The Role of PET-CT and MRI. ( 27173652 )
2016
43
Predisposing factors for poor prognosis of angiosarcoma of the scalp and face: Systematic review and meta-analysis. ( 27507124 )
2016
44
Vaginal epithelioid angiosarcoma: a rare case. ( 28002534 )
2016
45
Multidisciplinary approach to breast angiosarcoma in an elderly patient: Repeated local relapses and significant objective responses. ( 26872968 )
2016
46
Sudden death in an adolescent due to primary angiosarcoma of the right atrium. ( 27108450 )
2016
47
Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study. ( 27211551 )
2016
48
Prognostic Significance of Forkhead Box M1 (FOXM1) Expression and Antitumor Effect of FOXM1 Inhibition in Angiosarcoma. ( 27162541 )
2016
49
Pazopanib does not bring remarkable improvement in patients with angiosarcoma. ( 27569550 )
2016
50
Cutaneous angiosarcoma metastatic to small bowel with nodal involvement. ( 27895862 )
2016

Variations for Angiosarcoma

Expression for Angiosarcoma

Search GEO for disease gene expression data for Angiosarcoma.

Pathways for Angiosarcoma

Pathways related to Angiosarcoma according to GeneCards Suite gene sharing:

(show all 39)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.73 FLT1 FLT4 KDR KIT MUC1 MYC
2
Show member pathways
13.64 FLT1 FLT4 KDR KIT MYC TEK
3
Show member pathways
13.57 FLT1 FLT4 KDR KIT MYC TEK
4
Show member pathways
13.44 FLT1 FLT4 KDR KIT MYC TEK
5
Show member pathways
13.25 KIT MUC1 MYC TEK TP53 VEGFA
6
Show member pathways
13.17 FLT1 FLT4 KDR KIT TEK VEGFA
7
Show member pathways
12.91 FLT1 FLT4 KDR KIT TEK
8
Show member pathways
12.88 FLT1 FLT4 KDR KIT MYC TP53
9
Show member pathways
12.81 FLT1 FLT4 KDR VEGFA VWF
10
Show member pathways
12.61 FLT1 FLT4 KDR KIT TEK VEGFA
11 12.44 MYC TP53 VEGFA VIM
12
Show member pathways
12.43 FLT1 FLT4 KDR TP53
13
Show member pathways
12.36 FLT1 FLT4 KDR TP53
14
Show member pathways
12.32 FLT1 FLT4 KDR VEGFA
15
Show member pathways
12.29 FLT1 FLT4 KDR VEGFA
16 12.23 KDR MYC TP53 VEGFA
17 12.15 FLI1 FLT1 MYC TP53
18 12.14 FLT1 FLT4 KDR KIT MYC TEK
19 12 KDR PECAM1 TP53 VEGFA
20 11.98 FLT1 FLT4 KDR KIT TEK
21
Show member pathways
11.95 FLT1 FLT4 KDR MYC TEK TP53
22 11.93 MYC TP53 VIM
23 11.93 KDR MYC PROX1 VEGFA VIM
24
Show member pathways
11.91 FLT1 KDR VEGFA
25 11.84 FLT1 TEK VEGFA
26 11.82 MUC1 MYC TP53 VEGFA VIM
27
Show member pathways
11.8 KIT MYC VEGFA
28
Show member pathways
11.79 FLT1 FLT4 KDR VEGFA
29 11.78 FLT1 TEK VEGFA
30
Show member pathways
11.73 FLT1 FLT4 KDR KIT
31 11.67 MYC TP53 VEGFA
32 11.62 FLT1 KDR TP53 VEGFA
33 11.61 KIT MYC TP53
34
Show member pathways
11.61 FLT1 FLT4 KDR KIT
35 11.48 MYC TP53 VEGFA
36 11.26 FLT1 KDR VEGFA
37 11.11 FLT1 FLT4 KDR PECAM1 PROX1 TEK
38 11 FLT1 KDR TEK VEGFA
39
Show member pathways
10.66 FLT1 FLT4 KDR VEGFA

GO Terms for Angiosarcoma

Cellular components related to Angiosarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.4 FLT1 FLT4 KDR KIT KRT8 MUC1

Biological processes related to Angiosarcoma according to GeneCards Suite gene sharing:

(show all 37)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 KIT MYC TP53 VEGFA VIM
2 positive regulation of cell migration GO:0030335 9.89 FLT1 KDR KIT VEGFA
3 angiogenesis GO:0001525 9.89 FLT1 FLT4 KDR TEK VEGFA
4 positive regulation of protein phosphorylation GO:0001934 9.88 FLT4 KDR TEK VEGFA
5 positive regulation of cell proliferation GO:0008284 9.87 FLT1 FLT4 KDR KIT MYC PROX1
6 platelet degranulation GO:0002576 9.85 PECAM1 VEGFA VWF
7 positive regulation of angiogenesis GO:0045766 9.85 FLT1 KDR TEK VEGFA
8 protein autophosphorylation GO:0046777 9.83 FLT1 FLT4 KDR KIT TEK
9 cellular response to hypoxia GO:0071456 9.82 MYC TP53 VEGFA
10 positive regulation of MAPK cascade GO:0043410 9.81 FLT1 FLT4 KDR KIT
11 peptidyl-tyrosine phosphorylation GO:0018108 9.8 FLT1 FLT4 KDR KIT TEK
12 positive regulation of MAP kinase activity GO:0043406 9.78 FLT1 KIT VEGFA
13 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.78 FLT1 FLT4 KDR VEGFA
14 ovarian follicle development GO:0001541 9.76 KIT MYC VEGFA
15 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.76 FLT1 KDR KIT TEK
16 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.73 FLT1 KIT TEK
17 positive regulation of focal adhesion assembly GO:0051894 9.7 KDR TEK VEGFA
18 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.67 KIT PECAM1
19 megakaryocyte development GO:0035855 9.66 FLI1 KIT
20 embryonic hemopoiesis GO:0035162 9.66 KDR KIT
21 cell migration involved in sprouting angiogenesis GO:0002042 9.65 KDR VEGFA
22 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.65 FLT1 VEGFA
23 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.65 MUC1 TP53
24 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.65 FLT1 FLT4 KDR KIT TEK
25 lymph vessel development GO:0001945 9.63 FLT4 PROX1
26 lymphangiogenesis GO:0001946 9.63 FLT4 PROX1
27 positive regulation of positive chemotaxis GO:0050927 9.62 KDR VEGFA
28 positive regulation of phospholipase C activity GO:0010863 9.62 FLT1 KIT
29 positive regulation of protein kinase C signaling GO:0090037 9.61 FLT4 VEGFA
30 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.6 KDR VEGFA
31 vascular endothelial growth factor signaling pathway GO:0038084 9.54 FLT1 FLT4 KDR
32 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.46 FLT1 FLT4 KDR VEGFA
33 positive regulation of endothelial cell proliferation GO:0001938 9.35 FLT4 KDR PROX1 TEK VEGFA
34 positive regulation of endothelial cell migration GO:0010595 9.02 FLT4 KDR PROX1 TEK VEGFA
35 phosphorylation GO:0016310 10.07 FLT1 FLT4 KDR KIT TEK
36 protein phosphorylation GO:0006468 10.04 FLT1 FLT4 KDR KIT TEK
37 negative regulation of apoptotic process GO:0043066 10.01 FLT4 KDR MYC TEK TP53 VEGFA

Molecular functions related to Angiosarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.85 FLT1 FLT4 KDR KIT TEK
2 protein kinase activity GO:0004672 9.77 FLT1 FLT4 KDR KIT TEK
3 protein tyrosine kinase activity GO:0004713 9.65 FLT1 FLT4 KDR KIT TEK
4 protease binding GO:0002020 9.61 KIT TP53 VWF
5 growth factor binding GO:0019838 9.46 FLT1 FLT4 KDR TEK
6 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.4 KDR KIT
7 vascular endothelial growth factor-activated receptor activity GO:0005021 9.13 FLT1 FLT4 KDR
8 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.02 FLT1 FLT4 KDR KIT TEK
9 protein binding GO:0005515 10.2 FLI1 FLT1 FLT4 KDR KIT KRT8

Sources for Angiosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....